Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
5.8.2021 16:00:00 EEST | Business Wire | Press release
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. Host Inaugural Capital Markets Day for Investors and Analysts17.6.2026 20:10:00 EEST | Press release
IQM Quantum Computers Oy (f/k/a IQM Finland Oy), a global leader in full-stack superconducting quantum computers ("IQM," "IQM Quantum Computers" or the "Company"), today announced that its Capital Markets Day presentation is now available on IQM’s investor site at https://iqm.tech/ir/IQM-CapitalMarketDay-2026.pdf, following the event hosted at the Nasdaq MarketSite in New York City on June 15, 2026. The final edited webcast will be posted to and available on the Company's investor relations website in the coming days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617509971/en/ IQM CEO and Co-founder Jan Goetz presenting the company's growth strategy, technology roadmap, and commercial vision at the inaugural Capital Markets Day at Nasdaq MarketSite. The Capital Markets Day featured presentations from IQM's leadership team, providing investors, analysts, and industry stakeholders with an in-depth look at the Company's fin
The Smarter E Europe Sends a Strong Message: the Energy Future Is Renewable17.6.2026 17:09:00 EEST | Press release
Europe is once again facing an energy crisis, another reminder of just how vulnerable our fossil fuel-based energy system is. Yet the current crisis is also accelerating the energy transition and the adoption of electromobility. The objective is to reduce dependence on imports of fossil-based raw materials and thereby increase resilience. This year, The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, is sending a strong and clear message with its new special exhibit Renewables 24/7: Renewable energies ensure a secure, reliable and affordable energy supply every day, around the clock. This message is scientifically supported by a new study from the Fraunhofer Institute for Solar Energy Systems ISE, which will be presented on June 23. From June 23–25, around 2,800 exhibitors will present groundbreaking, market-ready and cross-system technologies for a 24/7 renewable energy supply at Messe München. More than 100,000 visitors are expected. This press rel
Xsolla Sponsors Game Camp France, Reinforcing Commitment to France’s Dynamic Games Ecosystem17.6.2026 16:47:00 EEST | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its sponsorship of Game Camp France this 18-19 June 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617351463/en/ Graphic: Xsolla The French video game industry is widely recognized as one of the most vibrant in Europe, with revenue reaching approximately €5.8 billion in 2025. Rather than a centralized market, it is a patchwork of regional scenes, each with its own communities, creative identity, and business dynamics. Game Camp France plays a key role in bringing these diverse voices together, creating a centralized space for collaboration, exchange, and growth. By sponsoring Game Camp France, Xsolla is investing directly in the local ecosystem and the developers who power it. Xsolla will be on-site to engage with studios, share insights, showcase its product offerings, and better understand the
The Estée Lauder Companies and Jo Malone London Launch Experience That Turns Visual Taste into a Personalized Fragrance Wardrobe, exclusively on Pinterest17.6.2026 16:26:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) and Jo Malone London today announced the launch of Scent Scanner, a first-of-its-kind experience available exclusively on Pinterest and rolling out in the US and France. The experience translates the visual preferences people have expressed across their Pinterest boards into personalized Jo Malone London fragrance recommendations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617962807/en/ Building on the success of Jo Malone London's AI Scent Advisor, introduced in 2025, Scent Scanner offers a new way for consumers to find their personalized scent, shifting the starting point from words to images. While the AI Scent Advisor invited consumers to describe the scent they were seeking, Scent Scanner reads visual inspiration – imagery, color palettes, textures, destinations, rituals and aesthetics – to suggest fragrances suited to each individual. The custom Pinterest experience bri
Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit17.6.2026 16:00:00 EEST | Press release
Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability risk assessment to address the blind spot that autonomous AI exploitation tools are increasingly able to find. With mean time to exploit (MTTE) collapsing from months to days or hours, the unmanaged Java estate has become an urgent enterprise security vulnerability. Azul’s assessment gives DevOps and SecOps teams complete visibility into the hidden risks embedded in the runtime of their Java estate before threat actors get there first, and is designed to complement the broader security, licensing and compliance solutions and services delivered by Azul’s trusted partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617352753/en/ Azul's JVM Vulnerability Risk Assessment dashboard. The Threat Landscape Has Transformed For most of Java’s enterprise history, a sophisticated exploit required a sophisticat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom